Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
123 hedge funds and large institutions have $737M invested in Five Prime Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 49 increasing their positions, 41 reducing their positions, and 42 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 41
17% less capital invested
Capital invested by funds: $892M → $737M (-$155M)
22% less funds holding
Funds holding: 157 → 123 (-34)
48% less call options, than puts
Call options by funds: $1.1M | Put options by funds: $2.13M
79% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$22M |
| 2 |
JP Morgan Chase
New York
|
+$5.77M |
| 3 |
AG
Artal Group
Luxembourg
|
+$4.68M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$4.66M |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$3.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$9.04M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.61M |
| 3 |
DM
Deerfield Management
New York
|
-$4.99M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.8M |
| 5 |
O
OppenheimerFunds
New York
|
-$4.52M |
FPRX Hedge Fund Activity: Q2 2017 in Review
123 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q2 2017, worth a combined $737M — down 17% from $892M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of FPRX and 9 opened new positions — a net loss of 33 holders — while 41 trimmed existing stakes and 49 added.
The largest buyer was Wellington Management Group, adding an estimated $22M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $9.04M sold.
- 123 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q2 2017, down from 157 in Q1 2017.
- Funds reported $737M of Five Prime Therapeutics, Inc. stock for Q2 2017, down 17% quarter-over-quarter.
- 9 funds opened new Five Prime Therapeutics, Inc. positions in Q2 2017 and 42 closed out, a net change of -33 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q2 2017 was Wellington Management Group, an estimated $22M added.
- The largest Five Prime Therapeutics, Inc. seller in Q2 2017 was Acadian Asset Management, an estimated $9.04M sold.
Based on aggregated 13F filings for Q2 2017.